- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01135251
Safety and Preliminary Evidence of Efficacy of Escalating Doses of Dimiracetam in AIDS Patients With Painful Neuropathy
June 1, 2010 updated by: Neurotune AG
A Double Blind, Parallel-group, Randomized Placebo Controlled, Multicentre Exploratory Study of Dimiracetam in Treatment Induced Painful Neuropathy in Patients With HIV Infection
One hundred consenting AIDS patients suffering from treatment induced painful neuropathy will be blindly randomize to Active and Placebo groups (ratio A/P = 3/2 and will receive increasing oral doses of dimiracetam starting from 400 mg b.i.d. and doubling the dose every two weeks until a maximum of 1600 mg b.i.d.
Escalation to the the higher dose is allowed only if the previous dose did not cause tolerability problems.
The highest reached dose will be maintained for a total of 8 week treatment.
Patients must have a self evaluated pain of at least 4 on a 10 cm visual analog scale (VAS).
Primary end point of the study will be the number of Adverse Events (AEs) reported in the placebo versus the active group.
Preliminary evidence of efficacy will be sought by comparing active and placebo group as to the intensity of their pain at study onset and at study end.
The pain will be evaluated by the VAS the Total Symptoms Score and the Clinical Global Impression
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
116
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Port Elizabeth, South Africa, 6001
- Aurora Hospital Triple Research
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 65 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- male and female aged 18-65 years;
- females of child-bearing potential only if using a medically accepted method of contraception with a second method of birth control, medically prescribed intrauterine device (IUD), or double barrier method (condom in combination with spermicidal) prior to screening and agreeing to continue its use during the whole duration of the study;
- HIV-positive patients treated with ARTs;
- CD4+ cell count > 200/L at the screening;
- patients affected by neuropathic pain caused by ARTs;
- naïve neuropathic patients or non-responders (residual pain ≥40 mm on the VAS) to standard neuropathy treatments. Drugs for neuropathic pain (NP) must be stopped at screening visit;
- pain intensity ≥40 mm on the VAS at screening;
- pain intensity ≥40 mm on the VAS as the mean of the values collected on the last 4 days prior to the start of treatment (baseline VAS);
- life expectancy of at least 6 months;
- ability to comprehend the full nature and purpose of the study, including possible risks and side effects;
- ability to co-operate with the Investigator or designee and to comply with the requirements of the entire study;
- signed written informed consent prior to inclusion in the study
Exclusion Criteria:
- pregnant or lactating females;
- patients with neuropathic pain due to other factors than the ARTs; any clinically significant underlying disease, according to the Investigator's clinical judgement;
- history of psychosis (e.g. schizophrenia or psychotic depression) or major depression ;
- any current axis I diagnosis including dementia, depression, psychosis, anxiety disorders, mental retardation;
- participation in the evaluation of any investigational drug within 3 months prior to screening (6 months in the neuropathic pain). Use of an investigational drug other than dimiracetam during the study is not permitted;
- treatment with neurostimulating devices such as spinal cord stimulation (SCS), acupuncture, homeopathic remedies for pain or any kind of surgical treatment or blockade for the pain in the 4 weeks prior to screening;
- treatment with any drug for neuropathic pain (NP) after the screening visit; requirement of more than 2 transfusions / month to achieve haemoglobin level > 8 g/dL;
- history of alcohol abuse (defined according to USDA dietary guidelines) or drug abuse during the last 3 months prior to screening;
- history of allergic response to neuropathic treatments or history of anaphylaxis or allergic reactions to drugs in general;
- any abnormality that the Investigator deems to be clinically relevant, either on medical history, physical examination, ECG or in diagnostic laboratory test;
- subjects likely to be non-compliant or uncooperative during the study according to the Investigator or designee's judgement
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: dimiracetam
Capsules containing 400 mg of dimiracetam will be administered orally, twice a day for 8 weeks in ascending schedule, contingent on tolerability of the previous dose, as follows: 1 capsule for two weeks (800mg/day), two capsules for the next two weeks (1600mg/day)and 4 capsules for the final 4 weeks (3200mg/day).
|
400 mg capsules for oral use to be administered twice a day for a total of 8 weeks
|
Placebo Comparator: sugar pill
capsules containing 400 mg of inert material will be orally administered twice a day with the same modalities used for the dimiracetam arm: one capsule for 2 weeks, 2 capsules for another 2 weeks and 4 capsules for 4 weeks
|
capsules containing 400 mg of inert material will be orally administered twice a day, one pill for 2 weeks, 2 pills for other 2 weeks and 4 pills for the last 4 weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
safety and preliminary evidence of efficacy
Time Frame: August 2010
|
August 2010
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Study Director: Ruggero G Fariello, MD FAAN, Neurotune AG
- Principal Investigator: Daniel R Malan, MD, Triple Research, Port Elizabeth SA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2009
Primary Completion (Actual)
March 1, 2010
Study Completion (Actual)
March 1, 2010
Study Registration Dates
First Submitted
June 1, 2010
First Submitted That Met QC Criteria
June 1, 2010
First Posted (Estimate)
June 2, 2010
Study Record Updates
Last Update Posted (Estimate)
June 2, 2010
Last Update Submitted That Met QC Criteria
June 1, 2010
Last Verified
June 1, 2010
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CRO-08-94/NT-11624/003
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neuropathy
-
Arash Asher, MDVoxxLifeRecruitingNeuropathy | Chemotherapy-induced Peripheral Neuropathy | Neuropathy;PeripheralUnited States
-
Henry Ford Health SystemOctapharma USA, Inc.RecruitingSmall Fiber Neuropathy | Autoimmune Small Fiber Neuropathy | Inflammatory Polyneuropathy | Immune-Mediated NeuropathyUnited States
-
Beth Israel Deaconess Medical CenterPhoenix Neurological Associates, LTDCompletedSmall Fiber Neuropathy | Idiopathic Peripheral NeuropathyUnited States
-
Nihon Pharmaceutical Co., LtdCompletedMultifocal Motor NeuropathyJapan
-
University of AarhusCompletedMultifocal Motor NeuropathyDenmark
-
Tanta UniversityCompletedDiabetic Neuropathies | Diabetic Peripheral Neuropathy | Painful Diabetic Neuropathy | Autonomic Neuropathy | Diabetic Polyneuropathy | Small Fiber NeuropathyEgypt
-
Yung-Tsan WuCompleted
-
Centre Hospitalier Universitaire de NīmesRecruiting
-
Haukeland University HospitalAarhus University HospitalCompletedDiabetes Mellitus | Peripheral Neuropathy | Autonomic Neuropathy | Small Fibre NeuropathyNorway
-
argenxRecruitingMultifocal Motor Neuropathy (MMN)United Kingdom, Spain, United States, Italy, Netherlands, Germany, France, Belgium, Canada, Poland, Austria
Clinical Trials on dimiracetam
-
Neurotune AGUnknownAcquired Immunodeficiency SyndromeSwitzerland